WO2000031285A1 - Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells - Google Patents

Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells Download PDF

Info

Publication number
WO2000031285A1
WO2000031285A1 PCT/NL1999/000717 NL9900717W WO0031285A1 WO 2000031285 A1 WO2000031285 A1 WO 2000031285A1 NL 9900717 W NL9900717 W NL 9900717W WO 0031285 A1 WO0031285 A1 WO 0031285A1
Authority
WO
WIPO (PCT)
Prior art keywords
adenovirus
cells
fiber
protein
vehicle according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL1999/000717
Other languages
English (en)
French (fr)
Inventor
Menzo Jans Emco Havenga
Abraham Bout
Ronald Vogels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Introgene BV
Original Assignee
Introgene BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgene BV filed Critical Introgene BV
Priority to CA2318492A priority Critical patent/CA2318492C/en
Publication of WO2000031285A1 publication Critical patent/WO2000031285A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Definitions

  • the present invention provides adenovirus derived vectors which can be used as cassettes to insert different adenoviral genes from different adenoviral serotypes at the required sites.
  • a vector capable of producing a chimaeric adenovirus whereby of course also a gene of interest can be inserted (for instance at the site of El of the original adenovirus) .
  • the chimaeric adenovirus to be produced can be adapted to the requirements and needs of certain hosts in need of gene therapy for certain disorders.
  • a packaging cell will generally be needed in order to produce sufficient amount of safe chimaeric adenoviruses .
  • Chimaeric viruses having only one non-native sequence in addition to an insertion or replacement of a gene of interest in the El region are also within the scope of the invention.
  • An immunogenic response to adenovirus that typically occurs is the production of neutralizing antibodies by the host. This is typically a reason for selecting a capsid protein like penton, hexon and/or fiber of a less immunogenic serotype .
  • Restenosis is characterized by progressive arterial remodeling, extracellular matrix formation and intimal hyperplasia at the site of angioplasty (Schwartz et al , 1993; Carter et al , 1994; Shi et al,1996).
  • NO is one of the vasoactive factors shown to be lost after PTCA-induced injury to the endothelial barrier (Lloyd Jones and Bloch, 1996) .
  • restoration of NO levels after balloon-induced injury by means of adenoviral delivery of ceNOS may prevent restenosis (Varenne et al, 1998) .
  • construct pWE/Ad.AflIIrITRfibl6 comprising Ad5 sequence 3534-31094 and 32794-35938, further comprising an adenovirus 16 gene encoding fiber protein.
  • HUVsmc were infected with increasing amounts of virus particles per cell (156, 312, 625, 1250, 2500, 5000) .
  • the fiber mutant all carry the Luciferase marker gene (Ad5Fibll .Luc : 1.1 x 10 12 vp/ml; Ad5Fib35Luc: 1.4 x 10 12 vp/ml ; Ad5Fib51Luc: 1.0 x 10 12 vp/ml) .
  • efficient infection of SMC is not a general trade of all subgroup B fiber molecules.
  • Clearly fiber 16 an fiber 11 are better suited for infection of SMC than fiber 35 and fiber 51. Nevertheless, all subgroup B fiber mutants ' tested infect SMC better as compared to Ad5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/NL1999/000717 1998-11-20 1999-11-22 Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells Ceased WO2000031285A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2318492A CA2318492C (en) 1998-11-20 1999-11-22 Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203921 1998-11-20
EP98203921.6 1998-11-20

Publications (1)

Publication Number Publication Date
WO2000031285A1 true WO2000031285A1 (en) 2000-06-02

Family

ID=8234363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1999/000717 Ceased WO2000031285A1 (en) 1998-11-20 1999-11-22 Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells

Country Status (12)

Country Link
JP (1) JP4683682B2 (https=)
AT (1) ATE296894T1 (https=)
AU (1) AU770780B2 (https=)
CA (1) CA2318492C (https=)
DE (1) DE69925567T2 (https=)
ES (1) ES2244145T3 (https=)
IL (1) IL133032A (https=)
MX (1) MXPA99010682A (https=)
NO (1) NO995697L (https=)
NZ (1) NZ501214A (https=)
WO (1) WO2000031285A1 (https=)
ZA (1) ZA997213B (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024730A3 (en) * 2000-09-20 2002-06-27 Crucell Holland Bv Transduction of dendritic cells using adenoviral vectors
WO2004106532A1 (en) * 2003-05-27 2004-12-09 Cytos Biotechnology Ag Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b
US6849446B2 (en) 2000-05-31 2005-02-01 University Of Saskatchewan Modified bovine adenovirus having altered tropism
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6974695B2 (en) 2000-11-15 2005-12-13 Crucell Holland B.V. Complementing cell lines
US7052881B2 (en) 1995-06-15 2006-05-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US11253608B2 (en) 2017-05-26 2022-02-22 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776067B2 (en) * 1999-03-04 2004-08-26 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020051A2 (en) * 1995-11-28 1997-06-05 Genvec, Inc. Vectors and methods for gene transfer to cells
WO1998022609A1 (en) * 1996-11-20 1998-05-28 Genzyme Corporation Chimeric adenoviral vectors
WO1998033929A2 (fr) * 1997-01-30 1998-08-06 Centre National De La Recherche Scientifique (Cnrs) Utilisation d'un polypeptide a titre de recepteur cellulaire des adenovirus
WO1998044121A1 (fr) * 1997-04-02 1998-10-08 Transgene S.A. Fibre adenovirale modifiee et adenovirus cibles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020051A2 (en) * 1995-11-28 1997-06-05 Genvec, Inc. Vectors and methods for gene transfer to cells
WO1998022609A1 (en) * 1996-11-20 1998-05-28 Genzyme Corporation Chimeric adenoviral vectors
WO1998033929A2 (fr) * 1997-01-30 1998-08-06 Centre National De La Recherche Scientifique (Cnrs) Utilisation d'un polypeptide a titre de recepteur cellulaire des adenovirus
WO1998044121A1 (fr) * 1997-04-02 1998-10-08 Transgene S.A. Fibre adenovirale modifiee et adenovirus cibles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FALLAUX F ET AL: "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses", HUM GENE THER., vol. 9, 1 September 1998 (1998-09-01), pages 1909 - 1917, XP002111070 *
GALL J ET AL: "Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes", J VIROL., vol. 70, no. 4, April 1996 (1996-04-01), pages 2116 - 2123, XP002050655 *
ROELVINK P ET AL: "The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F", J VIROL., vol. 72, no. 10, October 1998 (1998-10-01), XP002111071 *
WICKHAM T ET AL: "Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies", J VIROL., vol. 70, no. 10, October 1996 (1996-10-01), pages 6831 - 6838, XP002911349 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052881B2 (en) 1995-06-15 2006-05-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7105346B2 (en) 1995-06-15 2006-09-12 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7968087B2 (en) 1998-11-20 2011-06-28 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US7250293B2 (en) 1999-05-18 2007-07-31 Crucell Holland B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7270811B2 (en) 1999-05-18 2007-09-18 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6849446B2 (en) 2000-05-31 2005-02-01 University Of Saskatchewan Modified bovine adenovirus having altered tropism
WO2002024730A3 (en) * 2000-09-20 2002-06-27 Crucell Holland Bv Transduction of dendritic cells using adenoviral vectors
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US6974695B2 (en) 2000-11-15 2005-12-13 Crucell Holland B.V. Complementing cell lines
US7344883B2 (en) 2000-11-15 2008-03-18 Crucell Holland B.V. Complementing cell lines
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
WO2004106532A1 (en) * 2003-05-27 2004-12-09 Cytos Biotechnology Ag Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b
US11253608B2 (en) 2017-05-26 2022-02-22 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
US12280123B2 (en) 2017-05-26 2025-04-22 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes

Also Published As

Publication number Publication date
JP4683682B2 (ja) 2011-05-18
NZ501214A (en) 2002-02-01
IL133032A (en) 2007-06-03
AU5960099A (en) 2000-05-25
NO995697L (no) 2000-05-22
NO995697D0 (no) 1999-11-19
AU770780B2 (en) 2004-03-04
ES2244145T3 (es) 2005-12-01
MXPA99010682A (es) 2002-03-08
CA2318492A1 (en) 2000-06-02
ATE296894T1 (de) 2005-06-15
JP2000157289A (ja) 2000-06-13
IL133032A0 (en) 2001-03-19
CA2318492C (en) 2010-05-11
ZA997213B (en) 2000-05-22
DE69925567T2 (de) 2006-05-04
DE69925567D1 (de) 2005-07-07

Similar Documents

Publication Publication Date Title
US7968087B2 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
CA2364499C (en) Means and methods for fibroblast-like or macrophage-like cell transduction
US6803234B2 (en) Gene delivery vectors with cell type specificity for primary human chondrocytes
JP4472178B2 (ja) キメラアデノウイルス
AU2002315947B2 (en) Adenoviral vectors with cell type specificity for mesenchymal cells
AU2002315947A1 (en) Adenoviral vectors with cell type specificity for mesenchymal cells
US6869936B1 (en) Means and methods for fibroblast-like or macrophage-like cell transduction
AU770780B2 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1020529B1 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US20060104953A1 (en) Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
EP1191104A1 (en) Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
EP1191105A1 (en) Gene delivery vectors provided with a tissue tropism for T-lymphocytes
EP1195440A1 (en) Gene delivery vectors for stem cells
AU2001294348B2 (en) Transduction of chondrocytes using adenoviral vectors
CA2407518A1 (en) Adenovirus vectors with knobless fibers, and their uses
NZ527634A (en) Means and methods for synoviocyte cell transduction
AU2001294348A1 (en) Transduction of chondrocytes using adenoviral vectors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AZ BA BB BG BR BY CA CN CR CU CZ DM GD GE GH GM HR HU ID IN IS KE KG KP KR KZ LC LK LR LS MA MD MG MN MW PL RU SD SG SK SL TJ TM TR TT TZ UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2318492

Country of ref document: CA